AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
← PD-1 × VEGF bispecifics after ivonescimab
MK-2010
2 people · 2 posts
Records
That MK-2010’s data are entirely from China is itself an industry signal: Merck is willing to refill post-PD-1 through this path.
Other cases in this chapter
- ivonescimabmPFS 11.14 vs 5.82 mo, HR 0.51
- JS207 + XELOXEarly signal in 1L MSS/pMMR CRC
- pumitamigMulti-indication; TNBC sits under breast
Floor
The Innovation | Medicine@Innov_MedicineScore6060
Minhua Chu@chuminhua432Score6060